Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema

Award Number: R41CA183335
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/18/2014
PERIOD OF PERFORMANCE END DATE: 08/31/2015

Group Awards By:

View Award Description

Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema - DESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximately 20% of the 2.3 million breast cancer survivors in the US suffer this chronic condition following axillary lymph node dissection and radiation therapy. Current treatments for secondary lymphedema are limited to lifelong physiotherapies, which can cause substantial and even prohibitive financial, physical, and psychological strain for most patients. Clearly, there is an unmet yet urgent medical need for new approaches to treat lymphedema in breast cancer survivors. Interestingly, recent discoveries have shown that two human hormones-adrenomedullin (ADM) and intermedin (IMD/ADM2)-and their cognate receptors (CLR/RAMP1, 2, and 3 receptors) play critical roles in the regulation of lymphangiogenesis and endothelial permeability, and that adipose tissue-derived progenitor cells (ADRCs) can promote lymphatic vessel formation in lymphedema models. Because breast cancer survivors may be deprived of endothelial progenitor cells that are essential for the regeneration of lymphatic vessels, we hypothesize that a combination therapy that integrates a CLR/RAMP receptor ligand and ADRCs could be the most efficient approach to prevent the occurrence of or to reduce the debilitating effects of lymphedema. To realize the full potential of this combination therapy, a group of stable ADM and IMD analogs that exhibit prolonged bioactivity in vivo have been developed. Accordingly, we propose to investigate the potency of combination therapies that comprise ADRCs and select stable analogs in improving the regeneration of lymphatic vessels in a mouse secondary lymphedema model. Successful development of this novel combination therapy has the potential to decrease the debilitating effects of breast-cancer-related lymphedema among breast cancer survivors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2014 ( Subtotal = $225,000 )
2014	2014	ADEPTHERA LLC	3353 ALMA STREET	PALO ALTO	CA	94306	SANTA CLARA	USA	Cancer Treatment Research	000	1	9/18/2014	NEW	$225,000
														Subtotal = $225,000

Grand Total All Awards = $225,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema

Award Number: R41CA183335

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/18/2014

PERIOD OF PERFORMANCE END DATE: 08/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer